Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cormedix Inc (CRMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 182,091
  • Shares Outstanding, K 119,014
  • Annual Sales, $ 430 K
  • Annual Income, $ -26,830 K
  • 60-Month Beta 2.76
  • Price/Sales 437.31
  • Price/Cash Flow N/A
  • Price/Book 33.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.50 +9.00%
on 03/20/19
1.98 -17.42%
on 02/25/19
-0.17 (-9.67%)
since 02/21/19
3-Month
1.11 +47.30%
on 12/24/18
2.74 -40.33%
on 02/13/19
+0.50 (+43.42%)
since 12/21/18
52-Week
0.17 +861.76%
on 05/22/18
2.74 -40.33%
on 02/13/19
+1.40 (+610.87%)
since 03/21/18

Most Recent Stories

More News
CorMedix Inc. Announces Appointment of Phoebe Mounts as Executive Vice President and General Counsel

BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 21, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CRMD : 1.67 (+9.15%)
CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update

CRMD : 1.67 (+9.15%)
CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences

BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CRMD : 1.67 (+9.15%)
Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRMD : 1.67 (+9.15%)
CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14

BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 7, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CRMD : 1.67 (+9.15%)
CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors

BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CRMD : 1.67 (+9.15%)
Infection Control Seizes Headlines as Companies Look to Tackle Food-Borne Illnesses

The growing concern over infectious diseases developing in facilities, such as hospitals, has caused a demand for products to combat the spread. These diseases are caused by pathogenic microorganisms such...

AKAO : 0.56 (+3.70%)
CAG : 25.86 (+12.93%)
FLO : 20.52 (+1.89%)
CRMD : 1.67 (+9.15%)
PCTL : 0.1500 (unch)
Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SS&C Technologies Holdings,...

ALL : 94.36 (+1.42%)
LXRX : 7.99 (+3.23%)
SSNC : 63.25 (+1.80%)
AGN : 154.10 (+0.28%)
CRMD : 1.67 (+9.15%)
VEDL : 9.99 (-0.50%)
Biotech and Cannabis Stocks That Are Emerging

HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a...

ACB : 9.62 (-1.94%)
GWPH : 176.21 (+3.41%)
CRMD : 1.67 (+9.15%)
HSGX : 0.13 (-7.14%)
Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results

BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 30, 2019 / CorMedix Inc. (NYSE American: ), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CRMD : 1.67 (+9.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CRMD with:

Business Summary

CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular...

See More

Key Turning Points

2nd Resistance Point 1.65
1st Resistance Point 1.59
Last Price 1.67
1st Support Level 1.49
2nd Support Level 1.44

See More

52-Week High 2.74
Fibonacci 61.8% 1.76
Last Price 1.67
Fibonacci 50% 1.46
Fibonacci 38.2% 1.15
52-Week Low 0.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar